Science at our Core,
Patients in our Hearts

We aspire to change the trajectory for people with cancers and autoimmune diseases that need more effective treatment options. Through the application of groundbreaking scientific discoveries and tireless dedication, we aim to transform patient lives through pioneering treatments.

 

Clinical Trials

IO-202 as Monotherapy in Patients in AML and CMML

Status: Recruiting

Brief Summary: To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy.

Dose Escalation Study of IO-108 and IO-108+Pembrolizumab in Solid Tumors

Status: Not yet recruiting

Brief Summary: To assess safety and tolerability of increasing doses of IO-108 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).

  • Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cell inhibitory receptors. We are committed to conducting clinical trials to evaluate the safety and efficacy of investigational therapies to obtain the necessary marketing approvals that allow physicians to prescribe them so individuals may have broad access.

    In some circumstances, a treating physician may make a request to provide an unapproved therapy to a qualifying individual, which must be approved by the U.S. Food and Drug Administration (FDA) and supported by the pharmaceutical manufacturer. This is called an expanded access program (EAP), sometimes known as “compassionate use,” and refers to a potential pathway for a patient with a serious or life-threatening disease or condition to try an investigational therapy outside of a clinical trial when there is no comparable or satisfactory therapy available.

    We understand that some patients may wish to access our unapproved investigational drugs. At this stage of our development, we do not have the internal infrastructure in place nor enough clinical product or evidence of clinical safety and efficacy of our investigational drugs to support an expanded access program. Therefore, Immune-Onc Therapeutics does not currently offer an expanded access program.